Is Buying Iradimed Corporation (NASDAQ:IRMD) Here Good Idea?

IRadimed Corporation (NASDAQ:IRMD) Logo

Investors sentiment decreased to 1.16 in 2019 Q2. Its down 0.41, from 1.57 in 2019Q1. It is negative, as 9 investors sold IRadimed Corporation shares while 16 reduced holdings. 8 funds opened positions while 21 raised stakes. 3.39 million shares or 35.49% more from 2.51 million shares in 2019Q1 were reported.
Financial Bank Of Montreal Can reported 0% of its portfolio in IRadimed Corporation (NASDAQ:IRMD). 131,727 are held by Navellier & Assoc. Royal Savings Bank Of Canada holds 0% of its portfolio in IRadimed Corporation (NASDAQ:IRMD) for 27 shares. Marshall Wace Llp reported 74,416 shares. Rk Capital Ltd Liability holds 1.22% in IRadimed Corporation (NASDAQ:IRMD) or 193,574 shares. American Int Grp stated it has 0% of its portfolio in IRadimed Corporation (NASDAQ:IRMD). 163,919 are owned by Mondrian Invest Prtnrs Ltd. Atria Ltd Company reported 771,677 shares. Chicago Equity Prtn Limited Liability Com accumulated 20,000 shares or 0.02% of the stock. Geode Management Lc invested in 60,092 shares or 0% of the stock. Barclays Public Ltd Limited Liability Company invested in 0% or 2,843 shares. Federated Incorporated Pa invested 0% in IRadimed Corporation (NASDAQ:IRMD). Spark Investment Mgmt Lc invested in 0.05% or 35,300 shares. Fiera Cap Corporation owns 48,957 shares. Hm Payson And owns 4,360 shares.

The stock of Iradimed Corporation (NASDAQ:IRMD) registered a decrease of 6.47% in short interest. IRMD’s total short interest was 514,600 shares in September as published by FINRA. Its down 6.47% from 550,200 shares, reported previously. With 59,900 shares average volume, it will take short sellers 9 days to cover their IRMD’s short positions. The short interest to Iradimed Corporation’s float is 10.42%.

The stock increased 13.44% or $2.73 during the last trading session, reaching $23.04. About 107,591 shares traded or 35.98% up from the average. IRadimed Corporation (NASDAQ:IRMD) has risen 4.28% since September 13, 2018 and is uptrending. It has outperformed by 4.28% the S&P500.

Iradimed Corporation develops, manufactures, markets, and distributes magnetic resonance imaging compatible products, and related accessories and services in the United States and internationally. The company has market cap of $260.16 million. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets under the MRidium name; and MRI compatible patient vital signs monitoring system under the IRadimed name. It has a 35.02 P/E ratio. The firm also offers IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories; iMagox MRI pulse oximeter; and iMagox MRI oximeter remote and display products.

More notable recent IRadimed Corporation (NASDAQ:IRMD) news were published by: Seekingalpha.com which released: “UA, MDR, IT and AMKR among midday movers – Seeking Alpha” on July 30, 2019, also Globenewswire.com with their article: “IRADIMED CORPORATION Announces FDA 510(k) Clearance for Neonatal Pulse Oximetry and Capnography Monitoring Using its MRI-Compatible Patient Vital Signs Monitor – GlobeNewswire” published on April 02, 2019, Globenewswire.com published: “IRADIMED CORPORATION Names Leslie McDonnell as President and Chief Executive Officer – GlobeNewswire” on July 29, 2019. More interesting news about IRadimed Corporation (NASDAQ:IRMD) were released by: Finance.Yahoo.com and their article: “Here’s What IRadimed Corporation’s (NASDAQ:IRMD) P/E Ratio Is Telling Us – Yahoo Finance” published on May 21, 2019 as well as Globenewswire.com‘s news article titled: “IRADIMED CORPORATION to Hold 2019 Second Quarter Financial Results Conference Call on July 30th – GlobeNewswire” with publication date: July 16, 2019.

IRadimed Corporation (NASDAQ:IRMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.